5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside causes acute hepatic insulin resistance in vivo

Diabetes

Volumn 54, Issue 2, 2005, Pages 355-360

  Pencek, R Richard ^a   Shearer, Jane ^a   Camacho, Raul C ^a   James, Freyja D ^a   Lacy, D Brooks ^a   Fueger, Patrick T ^a   Donahue, E Patrick ^a   Snead, Wanda ^a   Wasserman, David H ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE DERIVATIVE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 5 AMINOIMIDAZOLE 4 CARBOXAMIDE 1 BETA D RIBOFURANOTIDE; ADENYLATE KINASE; GLUCAGON; GLUCOSE; SOMATOSTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; MALE; NONHUMAN; PRIORITY JOURNAL;

AMINOIMIDAZOLE CARBOXAMIDE; ANIMALS; BLOOD GLUCOSE; CYCLIC AMP; DOGS; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLYCOLYSIS; HYPERINSULINISM; INFUSIONS, INTRAVENOUS; INSULIN RESISTANCE; LIVER; MALE; PATCH-CLAMP TECHNIQUES; PORTAL VEIN; RIBONUCLEOTIDES;

EID: 12744277951     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.2.355     Document Type: Article

References (39)

1. Corton JM, Gillespie JG, Hawley SA, Hardie DG: 5-Aminoimidazole-4- carboxamide ribonucleoside: a specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 229:558-565, 1995
2. Bergeron R, Russell RR 3rd, Young LH, Ren JM, Marcucci M, Lee A, Shulman GI: Effect of AMPK activation on muscle glucose metabolism in conscious rats. Am J Physiol 276:E938-E944, 1999
3. Bergeron R, Previs SF, Cline GW, Perret P, Russell RR 3rd, Young LH, Shulman GI: Effect of 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 50:1076-1082, 2001
4. Musi N, Goodyear LJ: AMP-activated protein kinase and muscle glucose uptake. Acta Physiol Scand 178:337-345, 2003
5. Winder WW: AMP-activated protein kinase: possible target for treatment of type 2 diabetes. Diabetes Technol Ther 2:441-448, 2000
6. Musi N, Goodyear LJ: Targeting the AMP-activated protein kinase for the treatment of type 2 diabetes. Curr Drug Targets Immune Endocr Metabol Disord 2:119-127, 2002
7. Longnus SL, Wambolt RB, Parsons HL, Brownsey RW, Allard MF: 5-Aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside (AICAR) stimulates myocardial glycogenolysis by allosteric mechanisms. Am J Physiol Regul Integr Comp Physiol 284:R936-R944, 2003
8. Iglesias MA, Ye JM, Frangioudakis G, Saha AK, Tomas E, Ruderman NB, Cooney GJ, Kraegen EW: AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 51:2886-2894, 2002 (Erratum in Diabetes 52:223-224, 2003)
9. Carlson CL, Winder WW: Liver AMP-activated protein kinase and acetyl-CoA carboxylase during and after exercise. J Appl Physiol 86:669-674, 1999
10. Aiston S, Green A, Mukhtar M, Agius L: Glucose 6-phosphate causes translocation of phosphorylase in hepatocytes and inactivates the enzyme synergistically with glucose. Biochem J 377:195-204, 2004
11. Pencek RR, James F, Lacy DB, Jabbour K, Williams PE, Fueger PT, Wasserman DH: Interaction of insulin and prior exercise in control of hepatic metabolism of a glucose load. Diabetes 52:1897-1903, 2003
12. Morgan CR, Lazarow AL: Immunoassay of insulin: two antibody system: plasma insulin of normal, subdiabetic, and diabetic rats. Am J Med Sci 257:415-419, 1963
13. Hamilton KS, Gibbons FK, Bracy DP, Lacy DB, Cherrington AD, Wasserman DH: Effect of prior exercise on the partitioning of an intestinal glucose load between splanchnic bed and skeletal muscle. J Clin Invest 98:125-135, 1996
14. Chan T, Exton J: A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes. Anal Biochem 71:96-105, 1976
15. Golden S, Wals PA, Katz J: An improved procedure for the assay of glycogen synthase and phosphorylase in rat liver homogenates. Anal Biochem 77:436-445, 1977
16. Lloyd B, Burrin J, Smythe P, Alberti KG: Enzymatic fluorometric continuous-flow assays for blood glucose, lactate, pyruvate, alanine, glycerol, and 3-hydroxybutyrate. Clin Chem 24:1724-1729, 1978
17. Wynants J, Van Belle H: Single-run high-performance liquid chromatography of nucleotides, nucleosides, and major purine bases and its application to different tissue extracts. Anal Biochem 144:258-266, 1985
18. Ally A, Park G: Rapid determination of creatine, phosphocreatine, purine bases and nucleotides (ATP, ADP, AMP, GTP, GDP) in heart biopsies by gradient ion-pair reversed-phase liquid chromatography. J Chromatogr 575:19-27, 1992
19. Wasserman DH, Cherrington AD: Hepatic fuel metabolism during exercise: role and regulation. Am J Physiol 260:E811-E824, 1991
20. Bradley E, Zhang L, Newman J, Richards S, Clark M, Rattigan S: Acute, divergent effects of AICAR on insulin action in vivo (Abstract). Diabetes 52 (Suppl. 1):A344, 2003
21. Merrill GF, Kurth EJ, Hardie DG, Winder WW: AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol 273:E1107-E1112, 1997
22. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002
23. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174, 2001
24. Winder WW: Energy-sensing and signaling by AMP-activated protein kinase in skeletal muscle. J Appl Physiol 91:1017-1028, 2001
25. Hutber CA, Hardie DG, Winder WW: Electrical stimulation inactivates muscle acetyl-CoA carboxylase and increases AMP-activated protein kinase. Am J Physiol 272:E262-E266, 1997
26. Al-Khalili L, Krook A, Zierath JR, Cartee GD: Prior serum- and AICAR-induced AMPK activation in primary human myocytes does not lead to subsequent increase in insulin-stimulated glucose uptake. Am J Physiol Endocrinol Metab 287:E553-E557, 2004
27. Wojtaszewski JF, Jorgensen SB, Hellsten Y, Hardie DG, Richter EA: Glycogen-dependent effects of 5-aminoimidazole-4-carboxamide (AICA)-riboside on AMP-activated protein kinase and glycogen synthase activities in rat skeletal muscle. Diabetes 51:284-292, 2002
28. Musi N, Yu H, Goodyear LJ: AMP-activated protein kinase regulation and action in skeletal muscle during exercise. Biochem Soc Trans 31:191-195, 2003
29. Wasserman DH, Lacy DB, Goldstein RE, Williams PE, Cherrington AD: Exercise-induced fall in insulin and hepatic carbohydrate metabolism during exercise. Am J Physiol 256:E500-E508, 1989
30. Wasserman DH, Spalding JS, Lacy DB, Colburn CA, Goldstein RE, Cherrington AD: Glucagon is a primary controller of the increments in hepatic glycogenolysis and gluconeogenesis during exercise. Am J Physiol 257:E108-E117, 1989
31. Aschenbach WG, Hirshman MF, Fujii N, Sakamoto K, Howlett KF, Goodyear LJ: Effect of AICAR treatment on glycogen metabolism in skeletal muscle. Diabetes 51:567-573, 2002
32. Ercan-Fang N, Cannon MC, Rath VL, Treadway JL, Taylor MR, Nuttall FQ: Integrated effects of multiple modulators on human liver glycogen phosphorylase a. Am J Physiol Endocrinol Metab 283:E29-E37, 2002
33. Ercan N, Gannon MC, Nuttall FQ: Allosteric regulation of liver phosphorylase a: revisited under approximated physiological conditions. Arch Biochem Biophys 328:255-264, 1996
34. Aiston S, Hampson L, Gomez-Foix AM, Guinovart JJ, Agius L: Hepatic glycogen synthesis is highly sensitive to phosphorylase activity: evidence from metabolic control analysis. J Biol Chem 276:23858-23866, 2001
35. Camacho RC, Pencek RR, Lacy DB, James FD, Donahue EP, Wasserman DH: Portal venous 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside infusion overcomes hyperinsulinemic suppression of endogenous glucose output. Diabetes 54:373-382, 2005
36. Buhl ES, Jessen N, Schmitz O, Pedersen SB, Pedersen O, Holman GD, Lund S: Chronic treatment with 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside increases insulin-stimulated glucose uptake and GLUT4 translocation in rat skeletal muscles in a fiber type-specific manner. Diabetes 50:12-17, 2001
37. Buhl ES, Jessen N, Pold R, Ledet T, Flyvbjerg A, Pedersen SB, Pedersen O, Schmitz O, Lund S: Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes 51:2199-2206, 2002
38. Halseth AE, Ensor NJ, White TA, Ross SA, Gulve EA: Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations. Biochem Biophys Res Commun 294:798-805, 2002
39. Lihn AS, Jessen N, Pedersen SB, Lund S, Richelsen B: AICAR stimulates adiponectin and inhibits cytokines in adipose tissue. Biochem Biophys Res Commun 316:853-858, 2004